Sleep medicine is a dynamic field that addresses the diagnosis and treatment of sleep disorders, recognizing the profound impact sleep has on overall health and well-being. From insomnia to sleep apnea and narcolepsy, a spectrum of disorders is meticulously evaluated and managed to enhance sleep quality and duration. Central to this discipline is the comprehensive evaluation of patients through clinical history, physical examination, and specialized studies like polysomnography. By uncovering the root causes of sleep disturbances, personalized treatment plans can be developed, tailored to each individual's needs. These interventions encompass behavioral strategies, pharmacotherapy, continuous positive airway pressure (CPAP) therapy, and surgical procedures where necessary. Behavioral interventions, notably cognitive-behavioral therapy for insomnia (CBT-I), aim to modify unhealthy sleep habits and address underlying psychological factors contributing to sleep difficulties. Pharmacotherapy may be employed judiciously to alleviate symptoms, although long-term use is typically avoided due to potential side effects and dependency issues. Moreover, education on maintaining a regular sleep schedule, creating a conducive sleep environment, and minimizing stimulants before bedtime is integral to promoting healthy sleep habits and optimizing sleep hygiene. Through these concerted efforts, sleep medicine practitioners strive to enhance sleep quality, ultimately improving daytime functioning and overall quality of life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States